Deals In Depth: October 2020
Executive Summary
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.